Biohaven's Nurtec® ODT Extends Partnership with Rick Ware Racing for 2022 NASCAR Cup Series and NTT INDYCAR Series

Biohaven Pharmaceuticals announced today that Nurtec® ODT (rimegepant) extends its sponsorship for the second year as the primary partner for the No. 51 Rick Ware Racing entry during the entire 2022 NASCAR Cup Series Season and the NTT INDYCAR series, after a successful first season. Nurtec ODT is the first and only FDA-approved medication that's proven to both treat and prevent migraine attacks.

Rick Ware, team owner, commented, "We had a great season with Biohaven, Nurtec ODT and Cody this past year. The company and brand values align perfectly with Rick Ware Racing, and we could not be more excited to have them as a primary partner in 2022. Heading into this season, we are looking forward to elevating our on-track performance and continuing to support our racing fans, including people with migraine and the military community through our Military Salutes Program."

Takuma Sato, two-time INDY 500 Champion, joined the No. 51 team in December to compete full-time in the 2022 NTT INDYCAR Series.

Throughout 2021, Rick Ware Racing and Nurtec ODT participated in thirty-five (35) military base visits across the United States, including a trip to Hawaii in December for the 80th Anniversary of Pearl Harbor. During these visits, the team interacted with service members through mock pit stops, driver Q&As and photos. Over the course of the year, the Military Salutes program allowed for over 1,200 service members to be honored in May, and over $150,000 in funds donated to service members and first responders charities in partnership with Nine Line Apparel. Heading into 2022, the team plans on continuing the efforts to give back to those who continue to serve.

As part of the NASCAR season, Rick Ware Racing and Biohaven plan to extend its participation in the established Military Salutes Program and visit military bases across the country in a show of support and thanks to our troops.